Neumora Therapeutics Inc. has released a corporate presentation highlighting its ongoing efforts in neuroscience drug development. The company’s leadership team is comprised of experienced professionals, including co-founder and CEO Paul L. Berns, President Joshua Pinto, Ph.D., and Chief Scientific Officer Nick Brandon, Ph.D., among others. The presentation outlines Neumora’s pipeline, which targets major health concerns such as metabolic, neurodegenerative, and neuropsychiatric diseases. Key programs include NMRA-215, an NLRP3 inhibitor for obesity; NMRA-511, a V1aR antagonist for agitation in Alzheimer’s disease; NMRA-GCASE, a GCase activator for Parkinson’s disease; NMRA-CK1δ, a CK1δ inhibitor for ALS and Parkinson’s disease; Navacaprant, a KOR antagonist for major depressive disorder; and two M4 modulators, NMRA-898 and NMRA-861, for schizophrenia. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.